These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23374611)

  • 41. The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico.
    Garcia Perlaza J; Aziziyeh R; Zhou A; De Sousa Barbosa V; Amaya J; Caporale J; Alva ME; Forero J; Tanaka S; Suri G; Garcia D
    J Med Econ; 2021; 24(1):983-992. PubMed ID: 34325606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The burden of diabetes and its complications: trends and implications for intervention.
    Chaturvedi N
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S3-12. PubMed ID: 17343954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates.
    Al-Maskari F; El-Sadig M; Nagelkerke N
    BMC Public Health; 2010 Nov; 10():679. PubMed ID: 21059202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro-costing analysis].
    Rodríguez Bolaños Rde L; Reynales Shigematsu LM; Jiménez Ruíz JA; Juárez Márquezy SA; Hernández Ávila M
    Rev Panam Salud Publica; 2010 Dec; 28(6):412-20. PubMed ID: 21308167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The economic imperative to conquer diabetes.
    Fradkin J; Rodgers GP
    Diabetes Care; 2008 Mar; 31(3):624-5. PubMed ID: 18308686
    [No Abstract]   [Full Text] [Related]  

  • 46. Economic burden of hypercholesterolemia in high risk of cardiovascular disease population in Mexico.
    Gasca-Pineda R; Osorio-Hernández M; Mehta R; Escobedo-de-la-Peña J; Narváez-Oriani CA
    Arch Cardiol Mex; 2023; 93(3):328-335. PubMed ID: 37553116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The cost of treating type 2 diabetes (CODEIRE).
    Nolan JJ; O'Halloran D; McKenna TJ; Firth R; Redmond S
    Ir Med J; 2006; 99(10):307-10. PubMed ID: 17274175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost of Illness Analysis of Type 2 Diabetes Mellitus: The Findings from a Lower-Middle Income Country.
    Butt MD; Ong SC; Wahab MU; Rasool MF; Saleem F; Hashmi A; Sajjad A; Chaudhry FA; Babar ZU
    Int J Environ Res Public Health; 2022 Oct; 19(19):. PubMed ID: 36231911
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost of diabetes in adults in Australia.
    Lee CM; Colagiuri R; Magliano DJ; Cameron AJ; Shaw J; Zimmet P; Colagiuri S
    Diabetes Res Clin Pract; 2013 Mar; 99(3):385-90. PubMed ID: 23298663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diabetes Care in India.
    Joshi SR
    Ann Glob Health; 2015; 81(6):830-8. PubMed ID: 27108150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost, outcomes, treatment pathways and challenges for diabetes care in Italy.
    Grimaccia F; Kanavos P
    Global Health; 2014 Jul; 10():58. PubMed ID: 25024101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How should developing countries manage diabetes?
    Narayan KM; Zhang P; Williams D; Engelgau M; Imperatore G; Kanaya A; Ramachandran A
    CMAJ; 2006 Sep; 175(7):733. PubMed ID: 17001048
    [No Abstract]   [Full Text] [Related]  

  • 54. Quantifying a strategic view of diabetes technology impacts: a system dynamics approach.
    Edwards RA; Graham A; Williams M; Amati M; Wright C; Lee M; Walsh D; Hughes N
    Diabetes Technol Ther; 2009 Jul; 11(7):411-8. PubMed ID: 19580353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation.
    Pradeepa R; Mohan V
    Eur J Clin Nutr; 2017 Jul; 71(7):816-824. PubMed ID: 28422124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Projected Impact of Mexico's Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study.
    Sánchez-Romero LM; Penko J; Coxson PG; Fernández A; Mason A; Moran AE; Ávila-Burgos L; Odden M; Barquera S; Bibbins-Domingo K
    PLoS Med; 2016 Nov; 13(11):e1002158. PubMed ID: 27802278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.
    Marcellusi A; Viti R; Mecozzi A; Mennini FS
    Eur J Health Econ; 2016 Mar; 17(2):139-47. PubMed ID: 25427540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic burden of hepatitis B infection among patients with diabetes.
    Deshpande G; Klink AJ; Shenolikar R; Singer J; Eisenberg Lawrence DF; Krishnarajah G
    Hum Vaccin Immunother; 2016 May; 12(5):1132-40. PubMed ID: 27050021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Type 2 diabetes epidemic in Mexico. Burden of disease 1990-2021 analysis and implications for public policies.
    Montoya A; Gallardo-Rincón H; Silva-Tinoco R; García-Cerde R; Razo C; Ong L; Stafford L; Lenox H; Tapia-Conyer R
    Gac Med Mex; 2023; 159(6):474-486. PubMed ID: 38386876
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case.
    Arredondo A; Zúñiga A
    Diabetes Care; 2004 Jan; 27(1):104-9. PubMed ID: 14693974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.